Fig. 5From: HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapyEffects of hypoxia and hypoxia mimetics on FcγRIIb expression and its transcriptional regulation. a, Histograms showing expression of FcγRIIb on LD and HD monocytes cultured under 21% or 1% O2, b, and quantified using flow cytometry (n = 5 per group). c, Histograms showing expression of FcγRIIb on monocytes treated with DMOG or Roxadustat (Rox). d, and quantified using flow cytometry (n = 5–10 per group). e, FcγRIIb expression quantified using flow cytometry following dose titration of DMOG treatment of THP-1 cells (n = 3, bars show means ± SEM). f, FcγRIIb expression on untreated (U) and DMOG treated M0, M1 and M2 monocyte-derived macrophages (MDM), (n = 11 per group). g, Representative Western blot showing FcγRIIb expression in untreated or DMOG-treated (D) M1 macrophages for 2 donors. h, FcγR A:I ratio on monocytes, THP-1 cells and MDMs untreated or treated with DMOG or Roxadustat (Rox) (n = 5–11 per group). i, FcγRIIb expression (left) and FcγR A:I ratio (right) on monocytes following treatment with VH298 (n = 8). j, FcγRIIb expression (left) and FcγR A:I ratio (right) on DMOG-treated monocytes in the absence or presence of FM19G11 (FM19, n = 8). k, Representative Western blot showing c-Jun expression in Untreated (U) or DMOG-treated (D) monocytes l, combined Western blot data of fold change of c-Jun expression relative to HSC70 (n = 6). m, FcγRIIb expression and n, FcγR A:I ratio on DMOG-treated monocytes following c-Jun peptide treatment (c-Jun; n = 8). o, Representative histograms showing FcγRIIb expression on purified human untreated (U) monocytes transfected with scrambled control (Scram) siRNA, and DMOG-treated monocytes transfected with Scram, HIF2A or JUN siRNA, 24 h post-treatment. p, FcγRIIb expression and q, FcγR A:I ratio for 9–17 donors per group using flow cytometry following treatments stated in o. r, Representative Western blots showing FcγRIIb expression on untreated monocytes transfected with Scram siRNA, and DMOG-treated monocytes transfected with Scram, HIF2A or JUN siRNA. s, Combined Western blot data of fold change of FcγRIIb expression relative to HSC70 (n = 9). Each point on the graphs represents a unique donor and bars represent group means. Statistical significance was assessed using a paired two-tailed Wilcoxon test (*p < 0.05, **p < 0.01, ****p < 0.0001 and ns = non-significant). Also see Additional file 5: Fig. S5Back to article page